The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.

Interindividual variation is important in the response to metformin as the first-line therapy for type-2 diabetes mellitus (T2DM). Considering that OCT1 and MATE1 transporters determine the metformin pharmacokinetics, this study aimed to investigate the influence of SLC22A1 and SLC47A1 variants on the steady-state pharmacokinetics of metformin and the glycemic response. This research used the prospective-cohort study design for 81 patients with T2DM who received 500 mg metformin twice a day from six primary healthcare centers. SLC22A1 rs628031 A>G (Met408Val) and Met420del genetic variants in OCT1 as well as SLC47A1 rs2289669 G>A genetic variant in MATE1 were examined through the PCR-RFLP method. The bioanalysis of plasma metformin was performed in the validated reversed-phase HPLC-UV detector. The metformin steady-state concentration was measured for the trough concentration (Cssmin) and peak concentration (Cssmax). The pharmacodynamic parameters of metformin use were the fasting blood glucose (FBG) and glycated albumin (GA). Only SLC22A1 Met420del alongside estimated-glomerular filtration rate (eGFR) affected both Cssmax and Cssmin with an extremely weak correlation. Meanwhile, SLC47A1 rs2289669 and FBG were correlated. This study also found that there was no correlation between the three SNPs studied and GA, so only eGFR and Cssmax influenced GA. The average Cssmax in patients with the G allele of SLC22A1 Met408Val, reaching 1.35-fold higher than those with the A allele, requires further studies with regard to metformin safe dose in order to avoid exceeding the recommended therapeutic range.

Introduction

The incidence of diabetes mellitus (DM) in Indonesia is getting higher every year, reaching 2.1% increase since 2013 based on the 2018 National Basic Health Research report. Of the total population, 13.1% has a high level of fasting blood glucose [1]. Consequently, to prevent and decrease DM-induced mortality and morbidity, a good blood glucose management is needed [2].

During the period of 2013–2021, metformin had been listed in the Indonesian National Formulary along with other oral antidiabetic drugs, including glipizide, glimepiride, and glibenclamide, as a drug provided by primary healthcare centers [3]. Compared to other oral antidiabetic drugs, metformin has a better ability to decrease the level of HbA1c by 1.0–2.0% and has less hypoglycemia effects. However, it is known that the glycemic response to metformin is varied because 35–40% patients have not reached the target for fasting blood glucose [4]. Our previous research revealed high variability in metformin plasma steady-state concentration (PSSC), reaching >100x at the trough and 15x at the peak [5]. Genomic variation likely leads to patients’ variability in the drug pharmacokinetic and pharmacodynamic variability, including those of metformin [6]. Metformin has renal excretion as the major elimination pathway with >0.6 genetic component (rGC), indicating that genetic factor greatly affects the variability in metformin renal clearance [7]. Genetic variation has an influence on the protein function in metformin bioavailability or therapeutic effects.

With the hydrophilic property as a cationic species (>99.9%) at a physiological pH, the pharmacokinetics of metformin is effective depending the function of the transporters [8]. The main transporters that have a key role in the pharmacokinetics of metformin to date are Organic Cation Transporter1 (OCT1) and Multidrug and Toxin Extrusion1 (MATE1). Mainly expressed in the liver, OCT1 is a protein transporter that carries metformin to hepatocytes, the target of metformin action. The genetic variation in SLC22A1 as the OCT1 coding gene can change the protein function, leading to a reduced amount of metformin in the receptors and therefore a declined therapeutic response. A number of studies showed that SLC22A1 genetic variation resulted in varied steady-state concentration of metformin and various glycemic response [9-12]. Furthermore, latest studies found that such genetic variation was associated with metformin intolerance in the gastrointestinal tract [13,14].

In addition, the SLC47A1 is a MATE1 protein-coding gene mostly located in the apical membrane of renal tubular cells and canalicular membrane of hepatocytes. MATE1 transports metformin from hepatocytes to the bile and excretes metformin through the kidneys. Some research proved that the polymorphisms in SLC47A1 affect the pharmacokinetic variability as well as the glycemic response [15,16]. To date, however, the majority of metformin pharmacogenetic studies focus on the effects of OCT1 and MATE1 polymorphisms on glycemic control at various doses. Only one study has linked this to the minimum steady-state concentrations but not to the maximum [10], which is likely associated with a predisposition to lactic acidosis. Meanwhile, a large number of studies of the peak concentrations only focus on single administration of metformin to healthy volunteers for bioavailability-bioequivalence studies but not on repeated administration as an actual condition of metformin use among T2DM patients. Both transporters are known to play an important role in metformin bioavailability. In addition, metformin pharmacogenetic studies conducted prospectively in a similar dose with a control on the adherence factors remain extremely limited. Therefore, this prospective study aimed to analyze how the genetic variation in two metformin transporter encoding genes correlates with not only the glycemic response but also with the minimum and maximum steady-state concentrations.

Materials and methods

Recruitment of the subjects

T2DM patients administered metformin 500 mg twice daily for at least 2 weeks from six primary healthcare centers in Yogyakarta Special Province were involved. An explanation of the research, such as the objectives, the procedures for the participants to follow as well as the risks and benefits of the research were conveyed both orally and in writing directly to the eligible subjects. The subjects were allowed time to decide whether they would participate in the study. When they have verbally expressed their consent, they signed 2 (two) informed consent forms containing the consent to participate in the study (sheet 1) and to permit the research team to store and use their remaining specimens or DNA (sheet 2). The subjects recruited were in the 30–60 age range and literate, thus requiring no parent or guardian involvement in the subject recruitment procedure to indicate their consent to participate in this study. The ethical clearance was approved by the Ethics Committee of the faculty of Medicine of Universitas Gadjah Mada with the approval letter Number KE/FK/648/EC and conducted in accordance with the Declaration of Helsinki.

Analysis of the genotypes

The genotype analysis was done through Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP).

SLC22A1 (OCT1) rs628031 (Met408Val)

The PCR primer design used 5’-TTT CTT CAG TCT CTG ACT CAT GCC-3’ and 5’-AAA AAA CTT TGT AGA CAA AGG TAG CAC C-3’. The analysis of the 397-bp amplification products was done in 1% agarose gel followed by the restriction digestion in MscI with 16–18 hours of incubation at 37°C. The digestion yielded 397-bp fragments for the homozygous variants (val/val) as well as 210-bp and 187-bp fragments for the wild-type (Met/Met). The size of the digestion products (397 bp, 210 bp, and 187 bp) showed a category of heterozygotes (Met/Val). The genotype analysis were confirmed through the sequencing in a previous study [17].

SLC22A1 Met420del in OCT1

The PCR primer design used 5’-AGGTTCACGGACTCTGTGCT-3’ as the forward primer and 5’-AAGCTGGAGTGTGCGATCT-3’ as the reverse primer. The analysis of the 600-bp amplification products was done in 1% agarose gel at 100 Volt for 30 minutes, and the restriction digestion used BspHI with ±12 hours of incubation at 37°C. The T-CATGA sequence was cut by the BspHI enzyme at 197th DNA template base. The BspHI identified and digested the AA genotype, but this enzyme did not identify the PCR products with a T-CATTT sequence, making such products remain undigested. The digestion produced 600-bp fragments of AA (wild type) genotype, 403-bp and 197-bp fragments of aa (mutant) genotype, and 600-bp, 403-bp, 197-bp of heterozygotes (Aa).

SLC47A1 (MATE1) rs2289669 (G>A)

The PCR primer design used the forward primer of 5′-TCA GTT TCC ACA GTA GCG TCG-3′ and the reverse primer of 5′-GAC ACT GGA AGC CAC ACT GAA-3′. The TaqI restriction endonuclease digested the amplification products (211 bp), which were then analyzed in 2% agarose gel. The restriction digestion used the TaqI with 16–18 hours of incubation at 65°C. The 211-bp amplicons were digested into 21-bp and 190-bp fragments of AA genotype, 211-bp fragments of GG genotype/wild-type as well as 21-bp, 190-bp, and 211-bp fragments of heterozygous genotype [18].

Pharmacokinetics of metformin steady-state concentrations

The patients reported the time of the last metformin administration which was done for uniform doses and intervals. In 12 hours after the last dose administration, they visited the primary healthcare center for blood sampling to measure the same-day trough and peak concentrations. The sampling for the trough PSSC was immediately done before the next-dose administration (pre-dose), while the peak PSSC sample was taken in 3.5–4.0 hours after the metformin administration (post-dose). The samples were then delivered to the Laboratory of Drugs, Food, and Cosmetics of the Pharmacy Department of Universitas Islam Indonesia to be centrifuged for 10 minutes at 3500g, and the plasma aliquot was stored in a 2-ml polypropylene tube at -20°C in a maximum of one hour after the sampling. The metformin plasma concentrations were determined through a validated reversed-phase high performance liquid chromatography (HPLC) assay with Sunfire® C-18 column, 4.6 x 150mm x 5μm from Waters, and SM7 injector with an ultraviolet (UV) detector at 234 nm wavelength [19]. The metformin PSSC could estimate the elimination rate, and the metformin half-life was also calculated using the following formula [20].

Measurement of the glycemic response

The FBG and GA of T2DM patients given metformin monotherapy were measured before and after the continuous administration of metformin 500 mg twice daily for six weeks. The UV/VIS spectrophotometry of Hitachi 902® was used to measure FBG with the GOD-PAP method, and the ELISA reader of ADVIA® was employed in the measurement of GA with the KAOD (Ketoamine oxidase) method.

Statistical analysis

The metformin PSSC obtained was displayed in mean ± SD values. A comparison of patients’ metformin PSSC among the groups of allele types and genetic variants was made using the independent t-test and one-way ANOVA for normally distributed data as well as the Mann-Whitney and Kruskal-Wallis test for non-normal data distribution. To analyze the patient-related factors affecting the pharmacokinetics of metformin steady-state concentrations and glycemic control, the linier regression was employed with a statistically significant p value of ≤0.05.

Results and discussion

There have been no prospective studies of the influence of genetic polymorphisms on the pharmacokinetics of steady-state concentrations and glycemic response that involve T2DM patients who adhere to metformin therapy with a similar dose for a minimum of eight weeks. Given that metformin is a long-term antidiabetic drug, the pharmacokinetic variability of repeated administration can give a more accurate description of the concentration variability, while in a single-dose administration it is left unknown.

The discussion on the effects of genetic polymorphisms on the variability of the pharmacokinetics of steady-state concentrations and glycemic control resulted from metformin use should begin with an understanding of the function, physiological role of OCT1 and MATE1 protein transporters, as well as the level of gene expression in various human tissues. The following table describes the predicted pharmacokinetic variability of metformin steady-state concentrations and its glycemic response with regard to SNPs in SLC22A1 and SLC47A1 genes.

Meanwhile, the research findings related to the steady-state pharmacokinetic variability in each genetic variant and allele of both target genes are presented in Table 1.

Table 1

Variability of metformin steady-state concentrations according to the genetic variants and alleles.

Group of Patients	Frequency(%)	Cssmin (μg/mL)(P Value)	Cssmax (μg/mL)(P Value)
SLC22A1 Met408ValAAAGGG	5 (6.17)53 (64.43)23 (28.40)	0,358±0.2920.365±0.2440.347±0.3350.964	0.818±0.4451.323±0.8541.006±0.6540.144
SLC22A1 Met408ValA Allele (AA genotype)G Allele (AG and GG genotype)	5 (6.17)76 (93.83)	0.596±0.4860.600±0.453(0.986)	1.363±0.7431.845±0.9440.265
SLC22A1 Met420delAAAaAa	0 (0.00)3 (3.70)78 (96.30)	-0.549±0.2100.352±0.2720.222	2.831±0.5181.778±0.9280.015
SLC47A1 rs2289669GGGAAA	14 (17.28)35 (43.21)32 (39.51)	0.440±0.2590.316±0.3140.372±0.2210.337	1.298±0.5731.166±1.0301.202±5800.303
SLC47A1 rs2289669G Allele (GG genotype)A Allele (GA and AA genotype)	14 (17.28)67 (82.72)	0.720±0.4350.574±0.455(0.277)	1.846±0.7271.810±0.978(0.618)

Cssmax, maximum steady-state concentration; Cssmin, minimum steady-state concentration.

In general, Table 1 shows that the T2DM patients in the Javanese-Indonesian population have a significant difference in the Cssmax between the Aa and aa variants. As previously described in Table 2, OCT1 is highly expressed in the basolateral membrane of hepatocytes, making the polymorphisms able to reduce the protein function of OCT1 in transporting metformin into hepatocytes as the action target. As a result, metformin is retained in the systemic circulation at a higher concentration than in wild-type patients. Since such variant was not found in this study, no further comparative analysis could be performed. Although the difference was insignificant, a finding similar to the prediction was indicated by the difference in the mean Cssmax between the A allele and the G allele in SLC22A1 Met408Val, which was 1.363±0.743 g/mL and 1.845±0.944 g/mL, respectively. The presence of the rs628031 Met408Val polymorphisms in SLC22A1 is known to decrease the concentration of OCT1 mRNA in the human liver [21], resulting in reduced OCT1 function to transport metformin to hepatocytes. Consequently, polymorphisms in the SLC22A1 gene decrease the function of OCT1 in transporting metformin to hepatocytes, resulting in the highest Cssmax being found in the variant-type group. In relation to the risk of lactic acidosis, the G allele has the higher potential than the A allele. Given the accumulation of metformin concentration becomes a predisposition to metformin associated lactic acidosis (MALA), the maximum recommended dose of metformin, particularly on the G allele, should be considered. A number of studies have found that metformin accumulation leads to lactatemia either with or without decreased renal function [22,23]. In fact, there is a 6-fold increased risk of lactic acidosis in the initial use of metformin alongside a decreased renal function, and a 12–13 times higher risk is found in patients with cumulative exposure to high-dose metformin in the past year or initial exposure to high-dose metformin [24]. The administration of subtherapeutic dose is not a solution since the glycemic target is by no means achieved [25]. Metformin dose is not correlated with plasma lactate or serum creatinine as shown in a study involving the incidence of MALA for over 30 years of observation [26]. There is no examination of metformin concentration or control of adherence factors, making the accumulation of metformin in plasma remain a predisposing factor for MALA. However, other factors such as BMI [27] and comorbidities, including renal impairment, also clearly become the co-factors of metformin accumulation to induce MALA [28-30]. Not only the dose but also the long-term metformin use become a risk factor for metformin accumulation due to the distribution of metformin into the erythrocyte compartment as previously found in our study [5].

Table 2

Prediction of the steady-state pharmacokinetic variability and glycemic response affected by the genetic polymorphisms in SLC22A1 and SLC47A1.

Location of SNPs	Affected stage of metformin pharmacokinetics	Prediction of the effects of SNPs on the glycemic control parameters (FBG and GA) based on metformin Css as opposed to that of the wild-type variant
		Cssmax	Cssmin	Final FBG valuea	Changed FBG valueb	Final GA valuea	Changed GA valueb
SLC22A1 encoding OCT1 in the basolateral membrane of intestinal cells	Absorption	lower	minimum effect	higher	higher	higher	higher
SLC22A1 encoding OCT1 in the basolateral membrane of hepatocytes*	Influx to the action target in hepatocytes	higher	minimum effect	higher	higher	higher	higher
SLC47A1 encoding MATE1 in the hepatic canalicular membrane*	Efflux to the bile	lower	minimum effect	lower	lower	lower	lower
SLC22A1 encoding OCT1 in the apical membrane of renal tubular cells	Reabsorption in the renal tubules	lower	Lower	higher	higher	higher	higher
SLC47A1 encoding MATE1 in the brush-border membrane of renal tubular cells*	Efflux from the renal cells to be eliminated via urine	higher	higher	lower	lower	lower	lower

Note

*highly expressed [31]; aafter the administration of metformin 500 mg every 12 hours for 6 weeks.

bobtained from the final value of glycemic control (FBG, GA) minus the baseline value.

OCT1, organic cation transporter 1; MATE1, Multidrug and Toxin Extrusion 1; Cssmax, maximum steady-state concentration; Cssmin, minimum steady-state concentration; FBG, fasting blood glucose; GA, glycated albumin.

Using an approach of elimination half-life calculation based on the allele type in SLC22A1 Met408Val, this study found that the mean Cssmax was 1.35-fold higher in the G allele group (AG+GG) when compared to the wild-type group. A longer t1/2 (1.25 times) was also found in the GG homozygous mutant group (Val/Val) when compared to the AG heterozygous group (Met/Val). Therefore, it is recommended that the maximum dose of metformin for patients with the G allele (AG+GG) is lower than that for the wild-type group, and a longer interval of administration is recommended for the GG homozygous mutant group (Val/Val) in order to minimize the incidence of lactic acidosis.

Meanwhile, the SLC47A1 that encodes MATE1 is highly expressed in the canalicular membrane of hepatocytes in the bile and in the brush-border membrane of renal tubular cells. Each of which plays a role in the efflux to the bile and efflux from the kidney cells to be eliminated through urine, with predicted lower and higher Cssmax than those of the wild-type variant, respectively with the similar prediction for the glycemic response (Table 2). The mean metformin concentration in both the peak and trough PSSC is lower in the group of patients with the A allele of SLC47A1 rs2289669 when compared to the wild-type group although there is no significant difference. The likely decreased function of MATE1 in the canalicular membrane of hepatocytes in the bile which is more significant that in the brush-border membrane of renal tubular cells requires further studies.

It is found in our previous study that differences in the regimen of oral antidiabetic drugs and the duration of metformin use have led to significantly different mean of Cssmax and Cssmin, respectively. In addition, the linear regression analysis has shown that only the Cssmax, alongside the glycemic control factors, affect FBG and GA while the Cssmin has an influence on FBG. Therefore, this study proceeds with a linear regression test to further analyze the patient factors, including the genetic variants in the two target genes that influence the steady-level pharmacokinetics, glycemic response, and time estimates for metformin elimination to provide an approximation of the effective metformin dose as presented in Table 3.

Table 3

Patient-related factors correlated with glycemic response after the administration of metformin 1000mg/day for 6 weeks.

Dependent variable	Predictor	Coefficient	Coefficient of correlation	P value	ANOVA test result	Adjusted R Square in the Model Summary
Cssmin (μg/mL)	eGFR	-0.006	-0.246	0.026	0.015	0.093
	Variant genotype of SLC22A1 Met420del	-0.551	-0.231	0.043
	BMI	-0.020	-0.200	0.080
Cssmax (μg/mL)	eGFR	-0.013	-0.258	0.018	0.009	0.103
	Variant genotype of SLC22A1 Met420del	-1.430	-0.288	0.011
	BMI	-0.029	-0.135	0.228
Metformin elimination half-life	Duration of previous metformin therapy	3.696	0.254	0.022	0.029	0.064
	Allele type of SLC22A1 Met408Val	-4.542	-0.181	0.101
Final FBG	Baseline GA	3.093	0.463	0.004	0.001	0.333
	Variant genotype of SLC47A1 rs2289669	20.460	0.404	0.011
FBG change	Baseline FBG	3.135	0.347	0.078	0.000	0.621
	Baseline GA	-1.006	-0.968	0.000
	Variant genotype of SLC47A1 rs2289669	20.425	0.299	0.014
Final GA	Baseline GA	1.142	1.274	0.000	0.000	0.727
	Baseline FBG	-0.077	-0.749	0.001
	eGFR	0.086	0.305	0.020
	Variant genotype of SLC47A1 rs2289669	-0.889	-0.131	0.222
	Cssmin	-3.622	-0.176	0.244
	Cssmax	2.582	0.443	0.011
GA change	Baseline FBG	-0.793	-0.838	0.000	0.000	0.460
	eGFR	-0.060	0.353	0.039
	Variant genotype of SLC22A1 Met408Val	0.068	-0.192	0.182
	Cssmax	1.689	0.365	0.026

Cssmax, maximum steady-state concentration; Cssmin, minimum steady-state concentration; FBG, fasting blood glucose; GA, glycated albumin; eGFR, estimated-glomerular filtration rate; BMI, body mass index.

With regard to the use of glycemic control parameters, such as FBG and GA in this study but not HbA1c which is commonly used in the majority of metformin pharmacogenetic studies, a strong correlation between these three parameters has been demonstrated in some research [32-36]. The use of GA in Indonesia as both a diagnostic function and parameter for monitoring the success of diabetes therapy remains limited and has not become the gold standard of either the Indonesian Society of Endocrinology or the American Diabetic Association. However, GA is preferred for describing a glycemic control as opposed to HbA1c, especially in patients with impaired renal function or decreased life span of erythrocyte such as hemolytic anemia [37]. In addition, even with a shorter life span of albumin compared to that of HbA1c (±15 days), GA can describe the glycemic control in patients with diabetes mellitus for a minimum of 2–3 weeks [38], making it more appropriate for this study which involves adherent patients taking metformin for eight weeks (including metformin use duration as the inclusion criteria).

Together with eGFR and BMI, the SLC22A1 Met408del polymorphisms affect the pharmacokinetics of steady-state concentration of metformin with only a low adjusted R Square. This indicates that the two steady-state concentrations of metformin are mostly explained by other variables which are not involved in this study. Similarly, an extremely weak correlation is also shown by the SLC22A1 Met408del variant type alongside the duration of previous metformin use and the elimination half-life of metformin. Meanwhile, in the glycemic response based on FBG, only SLC47A1 rs2289669 affects both the decrease in and the final FBG values, particularly the decreased FBG with 0.621 adjusted R Square.

Encoded by the SLC47A1 gene, the metformin transporter MATE1 is mostly expressed in the apical membrane of renal tubular cells and canalicular membrane of hepatocytes. It has therefore a major role in the final phase of cationic organic compound excretion, including metformin [39]. On the other hand, a number of studies have investigated SLC47A1 rs2289669 polymorphisms and their effects on the pharmacokinetics, response, and other biochemical parameters for metformin. The rs2289669 polymorphisms interact with SLC22A1 rs594709, thus decreasing FBG and postprandial insulin as well as increasing HOMA-IR in the AA genotype group that has SLC22A1 and SLC47A1 as opposed to the group with a G allele [40]. Therefore, this study confirms the correlation between rs2289669 SLC47A1 polymorphisms and FBG values.

Meanwhile, when the final GA parameter is employed, none of the genetic variants studied affect it; instead, it is the baseline glycemic concentration, eGFR, and Cssmax with a good value of adjusted R Square of 0.727 that influence GA. In addition, changes in GA are affected by the baseline glycemic concentration, eGFR, and Cssmax. Such findings on the effects of rs2289669 SLC47A1 polymorphisms are different from those of other studies that use another parameter of glycemic response in metformin use. Research on the effects of rs2289669 on glycemic response to metformin using HbA1c reveals that the AA homozygous variant has the best glycemic response. This is probably caused by the reduced function of MATE1, which has an important role in the renal secretion of metformin, marked by a high AUC but low ClR among ten patients with such variant as opposed to those with other variants [18]. This result is similar to that of the research on 142 patients in Slovakia in which 20% of those with AA homozygous variant have two-fold reduced HbA1c after using metformin for six months [41]. Another similarity is found among 116 Caucasian patients with T2DM where those with the A allele SLC47A1 rs2289669 have 0.3% more reduction in HbA1c upon taking metformin [42]. Therefore, along with the baseline glycemic value and eGFR, the pharmacokinetics of maximum steady-state concentration (Cssmax) has a correlation with GA. The results of Cssmax examination in this study indicate that 64.6% patients have metformin concentrations in the therapeutic range (0.75–5 g/mL), and only 1/10 has Cssmin that is greater than or equal to 0.75 g/mL. This can possibly cause Cssmax to be the only parameter associated with GA. Therefore, these findings confirm the importance of adherence to metformin therapy to guarantee the achievement of metformin therapeutic concentrations.

Although the best efforts have been made through multicenter studies in some primary healthcare centers, there is a limitation in this study related to the number of patients involved. It becomes one of the factors in the incomprehensive analysis of the effects of polymorphisms on the pharmacokinetics of metformin steady-state concentrations and glycemic response. The difficulty in involving patients who are adherent to metformin therapy for a minimum of eight weeks is also a challenge for further studies.

Conclusion

In general, this study has found that the three polymorphisms absolutely have no effects on the pharmacokinetics of metformin steady-state concentrations. Although a further analysis involving other variables indicate the influence of SLC22A1 Met408del polymorphisms on the pharmacokinetics of metformin steady-state concentrations, the variables that are not studied here in fact play a more major role (>95%). Alongside the baseline glycemic value, rs2289669 SLC47A1 affects FBG while only eGFR and Cssmax influence GA, but the three SNPs studied do not. These findings lead to a recommendation of further studies involving more subjects for a safe approach of metformin dose, particularly in T2DM patients with the G allele SLC22A1 Met408del to prevent metformin accumulation beyond the recommended therapeutic range.

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

25 May 2022

28 Jun 2022

Vitarani D.A Ningrum

Department of Pharmacy

Universitas Islam Indonesia

Yogyakarta, Indonesia

June 29, 2022

Academic Editor

PLOS ONE

Thank you for your helpful comments. We have revised our paper accordingly and feel that your comments helped clarify and improve our paper. Please find below our responses:

1. Comments From Editor:

Please provide additional details regarding participant consent. In the Methods section, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information

These suggested edits have been completed (lines 108 – 117)

2. Comments From Editor:

The presentation can be improved; at some places, English grammar/usage can be improvised

We have rechecked the grammatical accuracy of the manuscript

3. Comments From Editor:

In table 2, comma instead of period is used as the decimal point indicator at some places.

These suggested edits have been completed (Table 2)

4. Comments From Editor:

% values are actually not noted in table 2

We have added % values in Table 2.

5. Comments From Editor:

For all tables & figures, provide keys for the abbreviations/acronyms that are used

These suggested edits have been added (Table 1., Table 2., and Table 3.)

6. Comments From Reviewer:

At some places authors mentioned they have recruited T2DM patients taking metformin for eight weeks.

But some places e.g. in methodology in Measurement of the Glycemic Response: its mentioned The FBG and GA of T2DM patients given metformin monotherapy were measured before and after the continuous administration of metformin 500 mg twice daily for six weeks.

Please explain

One of the inclusion criteria for this study is that the subject had been using metformin for a minimum of two weeks to ensure that the steady-state concentrations were achieved. A glycemic control examination was then performed at the beginning and six weeks after the routine use (the patient was confirmed to be compliant with the use of metformin during these six weeks). Therefore, in line with the reviewer's input, the author has revised the results and discussion section by adding such information (lines 106-107, 303-304)

7. Comments From Reviewer:

Minor concerns

Please give full form of MALA, eGFR.

These suggested edits have been completed (eGFR line 40; MALA line 228)

8. Comments From Reviewer:

Spelling error:

In introduction “Hipoglycemic”.

We have revised the word to hypoglycemia (line 61)

We appreciate your careful evaluation of our work and hope that this revision has addressed the comments and meets with your approval. We await your response.

Yours Sincerely,

Vitarani D.A Ningrum

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

30 Jun 2022

The Influence of Metformin Transporter Gene SLC22A1 and SLC47A1 Variants on Steady-state Pharmacokinetics and Glycemic Response

PONE-D-21-40655R1

Dear Dr. Ningrum,

We received your revised manuscript. The concerns raised in the last review have been adequately addressed, and I am pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Santosh K. Patnaik, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

13 Jul 2022

PONE-D-21-40655R1

The Influence of Metformin Transporter Gene SLC22A1 and SLC47A1 Variants on Steady-state Pharmacokinetics and Glycemic Response

Dear Dr. Ningrum:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Santosh K. Patnaik

Academic Editor

PLOS ONE